Avidity Biosciences Inc banner

Avidity Biosciences Inc
NASDAQ:RNA

Watchlist Manager
Avidity Biosciences Inc Logo
Avidity Biosciences Inc
NASDAQ:RNA
Watchlist
Price: 13.09 USD -0.83% Market Closed
Market Cap: $10B

Intrinsic Value

The intrinsic value of one RNA stock under the Base Case scenario is 6.12 USD. Compared to the current market price of 13.09 USD, Avidity Biosciences Inc is Overvalued by 53%.

RNA Intrinsic Value
6.12 USD
Overvaluation 53%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Get notified when the price drop
Track Buy Zone
20% below Intrinsic Value $4.9
Get notified when the price drops into your buy zone
Current Price $13.09
Intrinsic Value $6.12
Margin of Safety 20% $4.9
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about RNA?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is RNA valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Avidity Biosciences Inc.

Explain Valuation
Alternatives to RNA

Fundamental Analysis

Financials

Revenue & Expenses Breakdown
Avidity Biosciences Inc

Efficiency

Earnings Waterfall
Avidity Biosciences Inc

Wall St
Price Targets

Dividends

Avidity Biosciences Inc
does not pay dividends
Shareholder Yield

Competitive Landscape

Ownership

RNA Insider Trading
Buy and sell transactions by insiders

RNA News

What is the Intrinsic Value of one RNA stock?

The intrinsic value of one RNA stock under the Base Case scenario is 6.12 USD.

Is RNA stock undervalued or overvalued?

Compared to the current market price of 13.09 USD, Avidity Biosciences Inc is Overvalued by 53%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett